To evaluate the predictive power of the exosomal biomarkers CD40, CD25, and CA19-9 individually or in combination, a generalized linear model was used to discriminate PDAC patients from clinical controls and PDAC patients from pancreatitis patients. This evidence concerns the gene CD40 and pancreatitis.